All News

Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningfu…

Roche's Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) desig…

It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second coul…

The US FDA is set to review Kowa Pharmaceuticals America's NDA for K-911, an investigational once-daily eye dr…

Though its data could be useful for pharmaceutical firms, Polansky's latest entrepreneurial endeavor, Outer Bi…

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma's larg…

Since its immunology scholarship was established in 2016, AbbVie has supported more than 350 students living w…

Flagship Pioneering's ProFound Therapeutics is keeping its string of high-profile partnerships going, forging …

The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting fo…

Europe contemplates unified drug prices to counter US pressure to spend more. Experts are guarded in their exp…

Rasonque's speedy approval - just a month after a completed submission - represents a paradigm shift for a not…

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more …

The healthcare conglomerate, which ranks eighth on the Fortune 500 list, is set to envelop privately held Prec…

Phase 2 data on Spyre Therapeutics' anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of exp…

Oxford researchers call shingles shot first vaccine protecting both heart and brain. Lower heart disease risk …

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramat…

Alan Bash explains how Carvykti informed the company's strategy and what its in vivo platform still needs to p…

The campaign adds older adults to the obesity conversation and is anchored by Lilly's "A Life Covered" short f…

A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug develope…

By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework.…

Some comments on a proposed OMB research rule have been mysteriously removed from a public-facing government w…

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups ar…

The licensing deal marks a diversification of Roche's obesity pipeline as it seeks entry into the lucrative ma…